Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
JACKSONVILLE, Fla. and IRVINE, Calif., March 11, 2019 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., a pharmaceutical company focused on the development of therapeutics for unmet needs in thrombosis...
-
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., a pharmaceutical company focused on the development of late-stage drugs for unmet needs in thrombosis...
-
JACKSONVILLE, Fla. and IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., (“Espero”, or “the Company”), a pharmaceutical company focused on the development of late-stage drugs...
-
JACKSONVILLE, Fla., May 30, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, Inc., (the “Company”) a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to...
-
JACKSONVILLE, Fla. and IRVINE, Calif., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Espero BioPharma, a biopharmaceutical company focusing on the late-stage development and commercialization of drugs to treat...
-
- Pivotal Phase 3 trial for tecarfarin under FDA-approved Special Protocol Assessment provides clear regulatory pathway to the $8.5 billion U.S. oral anticoagulant market - JACKSONVILLE, Fla. and...